Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Safety of TV-46000 in Schizophrenia
NCT03893825Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Serious Adverse Events. Started Apr 2019; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03893825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893825.